Poseida Therapeutics, Inc. Revenue
Poseida Therapeutics, Inc. reported Revenue of $71.75 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2024-11-07
- Poseida Therapeutics, Inc. revenues for the quarter ending 2024-09-30 was $71.75M, a 667.19% increase year-over-year.
- Poseida Therapeutics, Inc. revenues for the quarter ending 2024-06-30 was $25.97M, a 29.78% increase year-over-year.
- Poseida Therapeutics, Inc. revenues for the quarter ending 2024-03-31 was $28.14M, a 172.09% increase year-over-year.
- Poseida Therapeutics, Inc. revenues for the quarter ending 2023-12-31 was $25.00M, a 148.68% increase year-over-year.
- Poseida Therapeutics, Inc. revenues for fiscal 2023 was $64.70M, a 50.42% decline from fiscal 2022.
- Poseida Therapeutics, Inc. revenues for fiscal 2022 was $130.49M, a 317.73% increase from fiscal 2021.
- Poseida Therapeutics, Inc. revenues for fiscal 2021 was $31.24M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2024-09-30 | $71.75M 10-Q · filed 2024-11-07 | $97.72M derived: sum of 2 quarters · filed 2024-11-07 | $125.86M 10-Q · filed 2024-11-07 | $150.86M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $25.97M 10-Q · filed 2024-08-05 | $54.12M 10-Q · filed 2024-08-05 | $79.11M derived: sum of 3 quarters · filed 2024-08-05 | $88.46M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $28.14M 10-Q · filed 2024-05-14 | $53.14M derived: sum of 2 quarters · filed 2024-05-14 | $62.49M derived: sum of 3 quarters · filed 2024-11-07 | $82.50M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $34.35M derived: sum of 2 quarters · filed 2024-11-07 | $54.36M derived: sum of 3 quarters · filed 2024-11-07 | $64.70M 10-K · filed 2024-03-07 |
| 2023-09-30 | $9.35M 10-Q · filed 2024-11-07 | $29.36M derived: sum of 2 quarters · filed 2024-11-07 | $39.71M 10-Q · filed 2024-11-07 | $49.76M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $20.01M 10-Q · filed 2024-08-05 | $30.36M 10-Q · filed 2024-08-05 | $40.41M derived: sum of 3 quarters · filed 2024-08-05 | $156.71M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $10.34M 10-Q · filed 2024-05-14 | $20.39M derived: sum of 2 quarters · filed 2024-05-14 | $136.70M derived: sum of 3 quarters · filed 2024-05-14 | $139.40M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $10.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $126.36M derived: sum of 2 quarters · filed 2024-03-07 | $129.06M derived: sum of 3 quarters · filed 2024-03-07 | $130.49M 10-K · filed 2024-03-07 |
| 2022-09-30 | $116.31M 10-Q · filed 2023-11-09 | $119.01M derived: sum of 2 quarters · filed 2023-11-09 | $120.44M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $2.70M 10-Q · filed 2023-08-08 | $4.13M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $1.44M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $31.24M 10-K · filed 2023-03-09 |